Loading
A phase 1/2 trial of rivoceranib (apatinib) and nab-paclitaxel in triple-negative breast cancer, run by Fujian Cancer Hospital, now recruiting.
Apatinib Combined with Albumin-Bound Paclitaxel for Treatment of Advanced Triple Negative Breast Cancer is a phase 1/2, interventional study registered as NCT05019690 by Fujian Cancer Hospital, with a registry enrolment figure of 29 participants, started 2021-10-01 and due to reach its primary completion in 2024-12-01. Interventions recorded: Apatinib Mesylate; Albumin-Bound Paclitaxel. Conditions listed: Advanced Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "Histologically or pathologically confirmed advanced triple-negative breast cancer that meets the following criteria:". Sites: China. No results are recorded here; the registry entry is the source.
Shares Rivoceranib (apatinib), Nab-paclitaxel, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Nab-paclitaxel, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.
Shares Rivoceranib (apatinib), Nab-paclitaxel, Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites) and the tag tnbc-deep-dive.
Shares Rivoceranib (apatinib), Metastatic triple-negative breast cancer, Triple-negative breast cancer trials open today (registry snapshot and UK sites), Cytotoxic chemotherapy and the tag tnbc-deep-dive.